Ownership and insider activity for Jupiter Neurosciences, Inc. (JUNS): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues.
Price
| Price | $2.93 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-31 | Cutler Andrew Jon | A-Award | 472,222 | $42K |
| 2026-07-22 | Cutler Andrew Jon | |||
| 2025-06-02 | Kampf Julie B. | M-Exempt | 82,875 | |
| 2025-06-02 | Kampf Julie B. | M-Exempt | 82,875 | |
| 2025-06-02 | Rosen Alexander Gustaf Erik | M-Exempt | 96,608 | |
| 2025-06-02 | Rosen Alexander Gustaf Erik | M-Exempt | 164,553 | |
| 2025-06-02 | Rosen Alexander Gustaf Erik | M-Exempt | 96,608 | |
| 2025-06-02 | Rosen Alexander Gustaf Erik | M-Exempt | 164,554 | |
| 2026-03-02 | Hayward Marshall A. | M-Exempt | 225,000 | |
| 2025-06-02 | Hayward Marshall A. | M-Exempt | 399,402 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1276 | $207998 | $330602 | $64431 | $28478 | $3.8M | $3.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | $126233 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | $159790 |
| Total Current Assets | $4968 | $549983 | $454674 | $69663 | $28739 | $4.7M | $4.8M |
| Property, Plant & Equipment | 0 | 0 | $208926 | $162498 | $116070 | $69642 | $23214 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $6177 | $549983 | $667383 | $235944 | $148592 | $6.2M | $5.6M |
| Accounts Payable | $131051 | $252192 | $256893 | $187032 | $189495 | $278676 | $131130 |
| Short-term Debt | $1.2M | $108479 | $440610 | $1.7M | $2.0M | $146432 | $5.3M |
| Total Current Liabilities | $5.0M | $4.3M | $5.7M | $7.3M | $5.8M | $2.0M | $7.4M |
| Long-term Debt | 0 | 0 | 0 | 0 | $106712 | 0 | 0 |
| Total Liabilities | $5.0M | $4.3M | $5.8M | $7.4M | $5.9M | $2.0M | $7.4M |
| Retained Earnings | -$8.0M | -$9.6M | -$13.8M | -$18.8M | -$23.6M | -$26.0M | -$34.7M |
| Total Equity | -$5.0M | -$3.7M | -$5.2M | -$7.1M | -$5.8M | $4.2M | -$1.8M |
| Total Debt | $1.2M | $108479 | $651201 | $1.9M | $2.2M | $217761 | $5.3M |
| Net Debt | $1.2M | -$99519 | $320599 | $1.8M | $2.2M | -$3.6M | $1.5M |
| Working Capital | -$5.0M | -$3.7M | -$5.2M | -$7.2M | -$5.7M | $2.6M | -$2.6M |
Financial Health
| Debt / Equity | -4.78 |
| Current Ratio | 0.66 |
Profitability
| Return on Equity | 747.33% |
| Return on Invested Capital | -709.40% |
| Return on Assets | -247.39% |
| Gross Margin | 88.34% |
| Operating Margin | -15166.68% |
| Net Margin | -14220.12% |
Related companies: ABVC · ALGS · FGEN · GNTA · GRCE · KZR · MRSN
Explore sector: Healthcare · Biotechnology
More sections of JUNS: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks